---
{"dg-publish":true,"permalink":"/entities/condition/amyotrophic-lateral-sclerosis/","tags":["condition","neurodegeneration","motor-neuron-disease","fatal"]}
---


# Amyotrophic Lateral Sclerosis

## Overview
Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, is a devastating motor neuron disease that selectively destroys upper motor neurons (in motor cortex) and lower motor neurons (in brainstem and spinal cord). The disease is uniformly fatal, with respiratory failure being the most common cause of death.

## Clinical Features

### Upper Motor Neuron Signs
- Spasticity
- Hyperreflexia
- Pathological reflexes (Babinski sign)

### Lower Motor Neuron Signs
- Muscle weakness and atrophy
- Fasciculations
- Hyporeflexia (in affected segments)

### Bulbar Symptoms
- Dysarthria (slurred speech)
- Dysphagia (swallowing difficulty)
- Sialorrhea (drooling)

## Pathophysiology
1. **TDP-43 Proteinopathy**: Cytoplasmic inclusions of TDP-43 in ~97% of cases
2. **SOD1 Mutations**: First identified ALS gene; toxic gain of function
3. **C9orf72 Expansion**: Most common genetic cause; dipeptide repeat toxicity
4. **Glutamate Excitotoxicity**: Excessive glutamate signaling
5. **Mitochondrial Dysfunction**: Impaired energy metabolism
6. **Oxidative Stress**: Free radical damage to motor neurons

## Genetic Forms (~10% familial)
- **C9orf72**: 40% of familial ALS; overlaps with FTD
- **SOD1**: 20% of familial ALS
- **TARDBP**: Encodes TDP-43
- **FUS**: RNA-binding protein

## Prognosis
- Median survival: 2-4 years from symptom onset
- 10% survive >10 years
- Respiratory muscle weakness determines survival

## Relationships

### Affected Regions
- → [[Motor Cortex\|Motor Cortex]] (organ) - *Upper motor neurons*
- → [[Spinal Cord\|Spinal Cord]] (organ) - *Lower motor neurons*
- → [[Brainstem\|Brainstem]] (organ) - *Bulbar motor neurons*

### Biomarkers
- ← [[entities/biomarker/Neurofilament Light Chain\|Neurofilament Light Chain]] (biomarker) - *Strongly elevated; prognostic value*
- ← [[Phospho-Neurofilament Heavy\|Phospho-Neurofilament Heavy]] (biomarker) - *CSF marker*
- ← [[entities/biomarker/Creatine Kinase\|Creatine Kinase]] (biomarker) - *Muscle damage marker*

### Diagnostic Tests
- ← [[EMG Electromyography\|EMG Electromyography]] (examination) - *Shows denervation*
- ← [[Nerve Conduction Studies\|Nerve Conduction Studies]] (examination) - *Normal sensory*
- ← [[MRI Brain and Spine\|MRI Brain and Spine]] (examination) - *Exclude mimics*

### Treatments
- ← [[Riluzole\|Riluzole]] (drug) - *Glutamate modulator; extends survival ~3 months*
- ← [[Edaravone\|Edaravone]] (drug) - *Antioxidant; slows decline in some patients*
- ← [[Non-Invasive Ventilation\|Non-Invasive Ventilation]] (intervention) - *Respiratory support*

### Related Conditions
- → [[entities/condition/Frontotemporal Dementia\|Frontotemporal Dementia]] (condition) - *ALS-FTD spectrum*
- → [[Primary Lateral Sclerosis\|Primary Lateral Sclerosis]] (condition) - *UMN-only variant*
- → [[Progressive Muscular Atrophy\|Progressive Muscular Atrophy]] (condition) - *LMN-only variant*

## References
1. **Review**: Feldman, E.L., et al. (2022). "Amyotrophic lateral sclerosis." *The Lancet*.
2. **Biomarkers**: Benatar, M., et al. (2018). "Neurofilament light in ALS." *Neurology*.
